DDInter458 DDInter1201
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy include metabolic abnormalities such as hypertriglyceridemia, insulin resistance, diabetes mellitus, and fatty liver disease. These metabolic abnormalities are often aggravated by excessive food intake, which is further aggravated by leptin deficiency, a protein secreted by adipose tissue. Administration of metreleptin results in improvement of metabolic symptoms including improvements in insulin resistance, reduced HbA1c and fasting glucose, reduced triglycerides, and reductions in food intake. Metreleptin is produced in _E. coli_ and differs from native human leptin by the addition of a methionine residue at its amino terminus. In February 2014, metreleptin was approved by the FDA for the treatment of complications of leptin deficiency, as an adjunct to diet, in patients with congenital generalized or acquired generalized lipodystrophy. Metreleptin was approved by Health Canada in January 2024 for the same patient population, in addition to patients with partial lipodystrophy.
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metreleptin
Cyclosporine {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Glipizide
Glipizide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Cyclosporine {u} (Compound) upregulates {v} (Gene) EPRS
EPRS {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metreleptin
Cyclosporine {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is upregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metreleptin
Cyclosporine {u} (Compound) upregulates {v} (Gene) EPRS
EPRS {u} (Gene) is upregulated by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Cyclosporine {u} (Compound) downregulates {v} (Gene) HSPA8
HSPA8 {u} (Gene) is downregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Cyclosporine {u} (Compound) downregulates {v} (Gene) RGS2
RGS2 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Cyclosporine {u} (Compound) upregulates {v} (Gene) TES
TES {u} (Gene) is downregulated by {v} (Compound) Theophylline
Theophylline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Cyclosporine {u} (Compound) upregulates {v} (Gene) CDK7
CDK7 {u} (Gene) is bound by {v} (Compound) Sorafenib
Sorafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Metreleptin
Cyclosporine {u} (Compound) downregulates {v} (Gene) STMN1
STMN1 {u} (Gene) is downregulated by {v} (Compound) Bortezomib
Bortezomib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metreleptin
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Glipizide (Compound) and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Cyclosporine (Compound) upregulates EPRS (Gene) and EPRS (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Cyclosporine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is upregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Cyclosporine (Compound) upregulates EPRS (Gene) and EPRS (Gene) is upregulated by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Cyclosporine (Compound) downregulates HSPA8 (Gene) and HSPA8 (Gene) is downregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Cyclosporine (Compound) downregulates RGS2 (Gene) and RGS2 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Cyclosporine (Compound) upregulates TES (Gene) and TES (Gene) is downregulated by Theophylline (Compound) and Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Cyclosporine (Compound) upregulates CDK7 (Gene) and CDK7 (Gene) is bound by Sorafenib (Compound) and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Metreleptin
Cyclosporine (Compound) downregulates STMN1 (Gene) and STMN1 (Gene) is downregulated by Bortezomib (Compound) and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin